Hadziyannis SJ et al. EASL. 2002. Peginterferon alfa-2a (40KD) (PEGASYS ® ) in combination with ribavirin (RBV): efficacy and safety results from a phase.

Slides:



Advertisements
Similar presentations
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin in GT 1-6 (Flat versus Weight-Based Ribavirin Dosing) WINR Study Phase 3 Treatment.
Advertisements

Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV versus Interferon alfa-2b RIBAVIC STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a versus Interferon alfa-2a Phase 3 Treatment Naïve, Chronic HCV Zeuzem S, et al. N Engl J.
Hepatitis web study Hepatitis web study PEG alfa-2a + RBV versus PEG alfa-2a versus INF + RBV APRICOT STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV vs. Peginterferon alfa-2a + RBV IDEAL STUDY Phase 3, Treatment Naïve Treatment Naïve,
Hepatitis web study Hepatitis web study Duration and Dose Finding Peginterferon alfa-2a + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Randomized study.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.
Hepatitis web study Hepatitis web study Peginterferon alfa -2a+/- Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV.
Hepatitis web study Hepatitis web study WINR Study Flat versus Weight-Based Ribavirin Dosing Phase 3 Treatment Naïve, Chronic HCV Jacobson IM, et. al.
Stefan ZEUZEM.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a +/- Ribavirin for Chronic HCV Phase 3 Treatment Naïve, Chronic HCV Fried MW, et. al. N Engl.
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,
Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.
ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.
OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.
Egyptian Ancestry  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI SOF 400 mg qd + RBV Randomised 1 : 1 Open-label Egyptian Ancestry Study:
SMV + PEG-IFN + RBV Open-label W12 W24* or W48* N = years Chronic HCV infection Genotype 4 Treatment-naïve or experienced with relapse or partial.
Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.
FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =
UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Ribavirin (Copegus, Rebetol, Ribasphere) Prepared by: David Spach, MD and H. Nina Kim,
Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.
Placebo + PR W48 Placebo + PR Yes Hezode C. Gut 2015;64: COMMAND-1 COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4 DCV60 + PEG-IFN.
SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.
ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.
W24 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve Early fibrosis to compensated cirrhosis No HBV or HIV co-infection N = 10 SOF + weight-based.
SOLAR-2 LDV/SOF + RBV Randomisation of the 7 groups 1 : 1 Open-label SOLAR-2 Study: LDV/SOF + RBV in decompensated and post-liver transplant with genotype.
Hepatitis web study Hepatitis web study Sofosbuvir + RBV in Treatment-Naïve Genotypes 2,3 FISSION Trial* Phase 3 *Note: Published in NEJM in tandem with.
> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.
SOF/VEL 400/100 mg qd N = 500 N = 100 W12 Placebo > 18 years Chronic HCV infection Genotype 1, 2, 4, 5 or 6 Naïve or pre-treatment with IFN-based regimen.
Sulkowski M. Lancet 2015;385: C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.
Asselah T. AASLD 2015, Abs OSIRIS  Design SMV + PEG-IFN + RBV Open label Chronic HCV infection Genotype 4 Treatment-naïve Mild to moderate fibrosis.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.
LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.
Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.
Dore G. J Hepatol 2016; 64:19-28 MALACHITE TVR + PEG-IFN + RBV Randomisation Open-label years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve (MALACHITE-I)
 Design Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a vs 1b) and ILB28 genotype (CC or non-CC) N = 134 N = 257 W24W48.
Poordad F. NEJM 2014;368: D Phase IIa  Design  Treatment regimens – Paritaprevir/rironavir (PTV/r) : PTV 250 or 150 mg qd/ritonavir 100 mg qd (2.
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
Maria Buti,1 Yoav Lurie,2 Natalia G. Zakharova,3 Natalia P. Blokhina,4 Andrzej Horban,5 Gerlinde Teuber,6 Christoph Sarrazin,6 Ligita Balciuniene,7 Saya.
Journal Conference Hepatology 2009;50: Background.
Phase 3 Treatment Experienced
Glecaprevir-Pibrentasvir in GT 1-6 with Renal Disease EXPEDITION-4
No HBV or HIV co-infection
Phase 3 Treatment-Naïve and Treatment-Experienced
CONCERTO-2 Study: SMV + PEG-IFNa-2a + RBV for genotype 1
Phase 3 Treatment-Naïve and Treatment-Experienced
No cirrhosis or compensated cirrhosis** No HBV or HIV co-infection
Creatinine clearance ≥ 50 ml/min No HBV or HIV co-infection
Phase 3 Treatment-Naïve and Treatment-Experienced
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1b TURQUOISE-III
QUARTZ II-III : OBV/PTV/r + SOF RBV in genotype 2 or 3
Phase 2 Treatment Naïve HIV Coinfection
SOF/VEL + GS-9857 in genotypes 1-6 Phase II
Simeprevir in HIV Coinfection, GT-1 C212 Trial
Phase 3 Treatment Naïve HIV Coinfection
Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
Phase 3 Treatment-Naïve and Treatment-Experienced
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3
Phase 2b Treatment Naïve and Treatment Experienced
ASPIRE Study: SMV + PEG-IFN + RBV for genotype 1 experienced patients
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 2 Treatment Experienced (with Sofosbuvir and Ribavirin)
Phase 3 Treatment-Naïve and Treatment-Experienced
CONCERTO-4 Study: SMV + PEG-IFNa-2b + RBV for genotype 1
Presentation transcript:

Hadziyannis SJ et al. EASL Peginterferon alfa-2a (40KD) (PEGASYS ® ) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose Professor Stephanos J. Hadziyannis Department of Medicine and Hepatology Henry Dunant Hospital Athens, Greece

Hadziyannis SJ et al. EASL Previous clinical studies with pegylated IFNs only investigated 48 weeks No prospective studies of the efficacy and safety of ribavirin doses have been conducted Therefore no evidence-based recommendation could be made Background

Hadziyannis SJ et al. EASL Study Aims To compare the efficacy and safety of the combination of PEGASYS ® and ribavirin given for 24 weeks vs. 48 weeks To compare the efficacy and safety of two different daily doses of ribavirin (low dose 800 mg vs. ‘standard’ dose of 1000/1200 mg) taken with PEGASYS ®

Hadziyannis SJ et al. EASL Study Design (1) Treatment-free follow-up of 24 weeks for all patients PEGASYS ® 180 µg sc qw + ribavirin 800 mg qd, 24 weeks PEGASYS ® 180 µg sc qw + ribavirin 1000/1200 mg qd, 24 weeks PEGASYS ® 180 µg sc qw + ribavirin 1000/1200 mg qd, 48 weeks PEGASYS ® 180 µg sc qw + ribavirin 800 mg qd, 48 weeks A : B : D : C : Total 1284 patients randomized and treated

Hadziyannis SJ et al. EASL Study Design (2) Randomization stratified by HCV genotype (1 vs. non-1) and viral titre (low vs. high, defined as  or >2 million copies/mL, respectively) and by geographic region Pre-planned distribution of genotypes – Genotype non 1 and 1 LVT 1:1:1:1 – Genotype 1 HVT1:1:4:4 Treatment duration blinded until week 24 Ribavirin dose blinded throughout study

Hadziyannis SJ et al. EASL Undetectable serum HCV RNA at the end of a 24-week treatment-free follow-up period (COBAS AMPLICOR ® HCV Test v2.0, sensitivity 50 IU/mL) Primary Endpoint

Hadziyannis SJ et al. EASL Main Inclusion Criteria Quantifiable HCV RNA in serum (AMPLICOR HCV MONITOR ® Test, v2.0) Elevated serum ALT levels Liver biopsy consistent with chronic HCV infection No previous interferon or ribavirin treatment

Hadziyannis SJ et al. EASL Main Exclusion Criteria Decompensated liver disease Coinfection with HIV or HBV Anaemia or expected inability to tolerate anaemia Significant co-morbid medical conditions

Hadziyannis SJ et al. EASL Patient Characteristics / / 1200 Male (%) Age (mean, y) Weight (mean, kg) weeks 48 weeks HCV RNA titre (mean, x10 6 copies/mL) Genotype 1 (%) Cirrhosis/ bridging fibrosis (%)

Hadziyannis SJ et al. EASL Results: SVR Genotype 1 24 weeks48 weeks SVR (%) 29% 41% 40% 51% n=101n=118n=250n=271 PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200 PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200

Hadziyannis SJ et al. EASL Results: SVR Genotype 1 Low Viral Titre 24 weeks48 weeks SVR (%) 41% 51% 53% 61% n=51n=71n=60n=85 PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200 PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200

Hadziyannis SJ et al. EASL Results: SVR Genotype 1 High Viral Titre 24 weeks48 weeks SVR (%) 16% 26% 35% 46% n=50n=47n=190n=186 PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200 PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200

Hadziyannis SJ et al. EASL Results: SVR Genotype Non-1 SVR (%) 24 weeks48 weeks 78% 73% 77% n=106n=162n=111n=165 PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200 PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200

Hadziyannis SJ et al. EASL Sustained Virologic Response: Effect of Cirrhosis SVR (%) 61% 65% 50% n=436n=321n=115 All patientsNon-cirrhoticsCirrhotics Treatment: PEGASYS ® + RBV 1000/1200 mg for 48 weeks

Hadziyannis SJ et al. EASL % Due to Adverse EventDue to Lab Abnormality 3.7% 0.9% 1.0% 12.4% 2.7% Rate of Withdrawal From Treatment 3.5% 14.2% 1.9% PEGASYS ® + RBV 800 mg, 24 weeks PEGASYS ® + RBV 1000/1200 mg, 24 weeks PEGASYS ® + RBV 800 mg, 48 weeks PEGASYS ® + RBV 1000/1200 mg, 48 weeks

Hadziyannis SJ et al. EASL Ribavirin Discontinuations for Adverse Events / Lab Abnormalities 24 weeks48 weeks Discontinuations (%) 7% 6% 18% 19% PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200 PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200

Hadziyannis SJ et al. EASL weeks48 weeks PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200 PEGASYS ® RBV 800 PEGASYS ® RBV 1000/1200 3% 7% 9% 10% % Serious Adverse Events 3%4%3% Treatment-related SAEs 1%

Hadziyannis SJ et al. EASL Summary (1) Overall SVR of 61% in patients treated for 48 weeks with PEGASYS ® and RBV 1000/1200 mg Overall safety profile similar to previous studies

Hadziyannis SJ et al. EASL Summary (2) Genotype 1 – 51% SVR achieved with 48 weeks treatment, 1000/1200 mg RBV – Shorter duration and/or lower RBV dose leads to reduction in efficacy

Hadziyannis SJ et al. EASL Summary (3) Genotype non-1 – SVR 78% 24 weeks with 800 mg RBV – Increasing duration and/or dose of RBV gave no increase in efficacy Shorter treatment associated with fewer SAEs and withdrawals for safety Lower dose RBV associated with fewer – SAEs (24 weeks) – RBV dose modifications – Large decreases in haemoglobin

Hadziyannis SJ et al. EASL Study Countries Norway UK Sweden Canada Ireland Denmark Belgium Finland USA Netherlands France Mexico GermanyTaiwan Brazil Portugal Spain Australia Italy New Zealand Greece 21 Countries